Patents by Inventor Hsin-Kang HSIEH

Hsin-Kang HSIEH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS AND USES THEREOF
    Publication number: 20180071295
    Abstract: Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor.
    Type: Application
    Filed: July 21, 2017
    Publication date: March 15, 2018
    Inventors: HSU-PING KUO, Hsin-Kang Hsieh, Betty Y. Chang, Ling Xue, Sriram Balasubramanian, Leo Cheung
  • Bruton's tyrosine kinase inhibitor combinations and uses thereof
    Patent number: 9730938
    Abstract: Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: August 15, 2017
    Assignees: Pharmacyclics LLC, Janssen Pharmaceutica NV
    Inventors: Hsu-Ping Kuo, Hsin-Kang Hsieh, Betty Chang, Ling Xue, Sriram Balasubramanian, Leo Cheung
  • BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS AND USES THEREOF
    Publication number: 20160038495
    Abstract: Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor.
    Type: Application
    Filed: August 6, 2015
    Publication date: February 11, 2016
    Inventors: Hsu-Ping KUO, Hsin-Kang HSIEH, Betty CHANG, Ling XUE, Sriram BALASUBRAMANIAN, Leo CHEUNG
  • BET INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS
    Publication number: 20160022684
    Abstract: Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g., ibrutinib) and a BET inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B cell malignancy, or a MYC-driven B cell malignancy comprising administering a combination of a BTK inhibitor (e.g., ibrutinib) and a BET inhibitor. Further disclosed herein are methods of evaluating a patient having a B-cell malignancy for treatment with a combination of a BTK inhibitor (e.g., ibrutinib) and a BET inhibitor based on the MYC expression level of the patient.
    Type: Application
    Filed: July 23, 2015
    Publication date: January 28, 2016
    Inventors: Hsu-Ping KUO, Hsin-Kang HSIEH, Betty CHANG